BACKGROUND: Retinoblastoma is the most common primary malignant intraocular neoplasm of childhood. The poor outcomes of patients with metastatic retinoblastoma have encouraged the search for new therapies. In the current study, the efficacy of combination therapy with calcitriol and cisplatin in athymic mice with subcutaneous Y-79 human retinoblastoma tumours was assessed. METHODS: 60 athymic mice were subcutaneously injected with human Y79 retinoblastoma cells. Animals were randomised into four groups: group 1, 50 microg of cisplatin; group 2, 0.05 microg of calcitriol; group 3, 0.05 microg of calcitriol and 50 microg of cisplatin; group 4, control. The cisplatin was administered once a week, and the calcitriol was given five times a week. RESULTS: There was a significant inhibition of tumour growth in animals treated with the combination therapy of calcitriol and cisplatin as compared with controls and cisplatin alone (p = 0.0001 and p = 0.0041 respectively). In terms of toxicity, serum calcium levels were increased, but there was no mortality and minimal nephrotoxicity in any of the groups. CONCLUSION: The present study shows that cisplatin given in combination with calcitriol may be a viable multidrug therapy option in the treatment of high-risk retinoblastoma.
BACKGROUND:Retinoblastoma is the most common primary malignant intraocular neoplasm of childhood. The poor outcomes of patients with metastatic retinoblastoma have encouraged the search for new therapies. In the current study, the efficacy of combination therapy with calcitriol and cisplatin in athymic mice with subcutaneous Y-79 humanretinoblastoma tumours was assessed. METHODS: 60 athymic mice were subcutaneously injected with human Y79 retinoblastoma cells. Animals were randomised into four groups: group 1, 50 microg of cisplatin; group 2, 0.05 microg of calcitriol; group 3, 0.05 microg of calcitriol and 50 microg of cisplatin; group 4, control. The cisplatin was administered once a week, and the calcitriol was given five times a week. RESULTS: There was a significant inhibition of tumour growth in animals treated with the combination therapy of calcitriol and cisplatin as compared with controls and cisplatin alone (p = 0.0001 and p = 0.0041 respectively). In terms of toxicity, serum calcium levels were increased, but there was no mortality and minimal nephrotoxicity in any of the groups. CONCLUSION: The present study shows that cisplatin given in combination with calcitriol may be a viable multidrug therapy option in the treatment of high-risk retinoblastoma.
Authors: Daniel G Dawson; Joel Gleiser; Michele L Zimbric; Soesiawaiti R Darjatmoko; Mary J Lindstrom; Stephen A Strugnell; Daniel M Albert Journal: Ophthalmology Date: 2003-04 Impact factor: 12.079
Authors: Isabelle Audo; Soesiawati R Darjatmoko; Cassandra L Schlamp; Janice M Lokken; Mary J Lindstrom; Daniel M Albert; Robert W Nickells Journal: Invest Ophthalmol Vis Sci Date: 2003-10 Impact factor: 4.799
Authors: Daniel M Albert; Robert W Nickells; David M Gamm; Michele L Zimbric; Cassandra L Schlamp; Mary J Lindstrom; Isabelle Audo Journal: Ophthalmic Genet Date: 2002-09 Impact factor: 1.803
Authors: Pamela A Hershberger; Terence F McGuire; Wei-Dong Yu; Eleanor G Zuhowski; Jan H M Schellens; Merrill J Egorin; Donald L Trump; Candace S Johnson Journal: Mol Cancer Ther Date: 2002-08 Impact factor: 6.261
Authors: Pierre Schlienger; François Campana; Jacques Robert Vilcoq; Bernard Asselain; Rémi Dendale; Laurence Desjardins; Thierry Dorval; Erica Quintana; José Rodriguez Journal: Am J Clin Oncol Date: 2004-08 Impact factor: 2.339
Authors: Amir A Azari; Mozhgan R Kanavi; Soesiawati R Darjatmoko; Vivian Lee; Kyungmann Kim; Heather D Potter; Daniel M Albert Journal: J Environ Pathol Toxicol Oncol Date: 2013 Impact factor: 3.567
Authors: Timothy W Corson; Brian C Samuels; Andrea A Wenzel; Anna J Geary; Amanda A Riley; Brian P McCarthy; Helmut Hanenberg; Barbara J Bailey; Pamela I Rogers; Karen E Pollok; Gangaraju Rajashekhar; Paul R Territo Journal: PLoS One Date: 2014-06-05 Impact factor: 3.240